The duty to disclose adverse clinical trial results.

Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results...

Full description

Bibliographic Details
Main Authors: Liao, S, Sheehan, M, Clarke, S
Format: Journal article
Language:English
Published: 2009
_version_ 1826273118684971008
author Liao, S
Sheehan, M
Clarke, S
author_facet Liao, S
Sheehan, M
Clarke, S
author_sort Liao, S
collection OXFORD
description Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.
first_indexed 2024-03-06T22:23:19Z
format Journal article
id oxford-uuid:55ccd54c-3c32-4fee-a2a3-38645a7be01f
institution University of Oxford
language English
last_indexed 2024-03-06T22:23:19Z
publishDate 2009
record_format dspace
spelling oxford-uuid:55ccd54c-3c32-4fee-a2a3-38645a7be01f2022-03-26T16:46:28ZThe duty to disclose adverse clinical trial results.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:55ccd54c-3c32-4fee-a2a3-38645a7be01fEnglishSymplectic Elements at Oxford2009Liao, SSheehan, MClarke, SParticipants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results to participants in clinical trials. This duty is grounded in the human right not to be placed at risk of harm without informed consent. We consider objections to disclosure grounded in considerations of commercial interest, and we argue that these concerns are insufficient to override the moral duty to disclose adverse clinical trial results. However, we also develop a proposal that enables commercial interests to be protected, while promoting the duty to disclose adverse clinical trial results.
spellingShingle Liao, S
Sheehan, M
Clarke, S
The duty to disclose adverse clinical trial results.
title The duty to disclose adverse clinical trial results.
title_full The duty to disclose adverse clinical trial results.
title_fullStr The duty to disclose adverse clinical trial results.
title_full_unstemmed The duty to disclose adverse clinical trial results.
title_short The duty to disclose adverse clinical trial results.
title_sort duty to disclose adverse clinical trial results
work_keys_str_mv AT liaos thedutytodiscloseadverseclinicaltrialresults
AT sheehanm thedutytodiscloseadverseclinicaltrialresults
AT clarkes thedutytodiscloseadverseclinicaltrialresults
AT liaos dutytodiscloseadverseclinicaltrialresults
AT sheehanm dutytodiscloseadverseclinicaltrialresults
AT clarkes dutytodiscloseadverseclinicaltrialresults